Form 8-K · Current report
UDR, Inc. 8-K, filed Nov 2, 2026
- Filed
- CIK
- 0000074208
- Accession no.
- 0000074208-26-000084
Summary
UDR, Inc. reported third-quarter 2026 results and raised its full-year 2026 guidance ranges for net income, FFOA per diluted share, and same-store growth while updating its FFO per diluted share range. The company also closed a $2.0 billion strategic partnership with Apollo by contributing 19 apartment communities and received $1.34 billion in equity capital.
Key points
- UDR reported third-quarter 2026 net income per diluted share of $0.67, FFO of $0.62, and FFOA of $0.65.
- Third-quarter same-store revenue grew 1.8% year over year, expenses rose 2.2%, and NOI rose 1.6%.
- UDR closed a $2.0 billion strategic partnership with Apollo by contributing 19 apartment communities totaling 7,059 apartment homes; UDR received $1.34 billion of equity capital and retained an approximate one-third interest.
- Through October, UDR repurchased approximately 5.2 million shares at a weighted average price of $35.48 for total consideration of approximately $185.1 million.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On November 2, 2026, UDR, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026. This press release is furnished as Exhibit 99.1 to this Report and refers to supplemental financial information that is available on the Company’s website and furnished as Exhibit 99.2 to this Report. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.